Lanthanum Carbonate Versus Sevelamer Hydrochloride: Improvement of Metabolic Acidosis and Hyperkalemia in Hemodialysis Patients

Therapeutic Apheresis and Dialysis

Volumn 15, Issue 1, 2011, Pages 20-27

  Filiopoulos, Vassilis ^a   Koutis, Ioannis ^a   Trompouki, Sofia ^a   Hadjiyannakos, Dimitrios ^a   Lazarou, Dimitrios ^a   Vlassopoulos, Dimosthenis ^a  

^a AMALIA FLEMING GENERAL HOSPITAL   (Greece)

Author keywords

Hemodialysis; Hyperkalemia; Hyperphosphatemia; Lanthanum carbonate; Metabolic acidosis; Sevelamer hydrochloride

Indexed keywords

ALKALINE PHOSPHATASE; BICARBONATE; CALCIUM ION; LANTHANUM CARBONATE; PHOSPHATE; POTASSIUM ION; SEVELAMER;

ACID BASE BALANCE; ADULT; AGED; ARTICLE; BICARBONATE BLOOD LEVEL; BONE METABOLISM; CLINICAL ARTICLE; DRUG DOSE TITRATION; DRUG SUBSTITUTION; FEMALE; GASTROINTESTINAL SYMPTOM; HEMODIALYSIS PATIENT; HUMAN; HYPERKALEMIA; MALE; METABOLIC ACIDOSIS; MINERAL METABOLISM; NAUSEA; NUTRITION; PH; PHOSPHATE BLOOD LEVEL; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; TASTE DISORDER;

ACIDOSIS; AGED; DIALYSIS SOLUTIONS; FEMALE; HUMANS; HYPERKALEMIA; KIDNEY FAILURE, CHRONIC; LANTHANUM; MALE; MIDDLE AGED; POLYAMINES; PROSPECTIVE STUDIES; RENAL DIALYSIS;

EID: 79251556862     PISSN: 17449979     EISSN: 17449987     Source Type: Journal    
DOI: 10.1111/j.1744-9987.2010.00868.x     Document Type: Article

References (29)

1. Hutchison AJ. Oral phosphate binders. Kidney Int 2009;75:906-14.
2. Hruska KA, Mathew S, Lund R, Qiu P, Pratt R. Hyperphosphatemia of chronic kidney disease. Kidney Int 2008;74:148-57.
3. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int 2009;76(Suppl 113):S1-130.
4. Frazão JM, Adragão T. Treatment of hyperphosphatemia with sevelamer hydrochloride in dialysis patients: effects on vascular calcification, bone and a close look into the survival data. Kidney Int 2008;74(Suppl 111):S38-S43.
5. Sprague SM. A comparative review of the efficacy and safety of established phosphate binders: calcium, sevelamer and carbonate. Curr Med Res Opin 2007;23:3167-75.
6. De Santo NG, Frangiosa A, Anastasio P etal. Sevelamer worsens metabolic acidosis in hemodialysis patients. J Nephrol 2006;19(Suppl 9):S108-S114.
7. Sonikian MA, Pani IT, Iliopoulos AN, Koutala KG, Marioli SI, Vlassopoulos DA. Metabolic acidosis aggravation and hyperkalemia in hemodialysis patients treated by sevelamer hydrochloride. Ren Fail 2005;27:143-7.
8. Oka Y, Miyazaki M, Takatsu S etal. Sevelamer hydrochloride exacerbates metabolic acidosis in hemodialysis patients, depending on the dosage. Ther Apher Dial 2007;11:107-13.
9. Sonikian M, Metaxaki P, Iliopoulos A, Marioli S, Vlassopoulos D. Long-term management of sevelamer hydrochloride-induced metabolic acidosis aggravation and hyperkalemia in hemodialysis patients. Ren Fail 2006;28:411-8.
10. Chiu YW, Kopple JD, Mehrotra R. Correction of metabolic acidosis to ameliorate wasting in chronic kidney disease: goals and strategies. Semin Nephrol 2009;29:67-74.
11. Daugirdas JT. Simplified equations for monitoring Kt/V, PCRn, eKt/V, and ePCRn. Adv Ren Replace Ther 1995;2:295-304.
12. Hemodialysis Adequacy 2006 Work Group. Clinical practice guidelines for hemodialysis adequacy, update 2006. Am J Kidney Dis 2006;48(Suppl 1):S2-90.
13. Adrogue HJ, Madias NE. Changes in serum potassium concentration during acute acid-base disturbances. Am J Med 1981;71:456-67.
14. Bommer J, Locatelli F, Satayathum S etal. Association of predialysis serum bicarbonate levels with risk of mortality and hospitalization in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2004;44:661-71.
15. Wu DY, Shinaberger CS, Regidor DL, McAllister CJ, Kopple JD, Kalantar-Zadeh K. Association between serum bicarbonate levels and death in hemodialysis patients: is it better to be acidotic or alkalotic? Clin J Am Soc Nephrol 2006;1:70-8.
16. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003;42(Suppl 3):S1-201.
17. Brezina B, Quinibi WY, Nolan CR. Acid loading during treatment with sevelamer hydrochloride. Mechanisms and clinical implications. Kidney Int 2004;66(Suppl 90):S39-45.
18. Wrong OM, Harland CE. Sevelamer-induced acidosis. Kidney Int 2005;67:776.
19. Moe SM, Chertow GM. The case against calcium-based phosphate binders. Clin J Am Soc Nephrol 2006;1:697-703.
20. Brancaccio D, Cozzolino M. Lanthanum carbonate: time to abandon prejudices? Kidney Int 2007;71:190-2.
21. Hutchison AJ, Barnett ME, Krause R, Kwan JTC, Siami GA on behalf of the SPD405-313 Lanthanum Study Group. Long-term efficacy and safety profile of lanthanum carbonate: results for up to 6years of treatment. Nephron Clin Pract 2008;110:15-23.
22. Hutchison AJ, Laville M. SPD405-313 Lanthanum Study Group. Switching to lanthanum carbonate monotherapy provides effective phosphate control with a low tablet burden. Nephrol Dial Transplant 2008;23:3677-84.
23. Sprague SM, Ross EA, Nath SD, Zhang P, Pratt RD, Krause R. Lanthanum carbonate vs sevelamer hydrochloride for the reduction of serum phosphorus in hemodialysis patients: a crossover study. Clin Nephrol 2009;72:252-8.
24. Malluche HH, Siami GA, Swanepoel C etal. Monier-Faugere MC on behalf of the SPD405-307 Lanthanum Carbonate Study Group. Improvements in renal osteodystrophy in patients treated with lanthanum carbonate for two years. Clin Nephrol 2008;70:284-95.
25. Raggi P, James G, Burke SK etal. Decrease in thoracic vertebral bone attenuation with calcium-based phosphate binders in hemodialysis. J Bone Miner Res 2005;20:764-72.
26. Regidor DL, Kovesdy CP, Mehrotra R etal. Serum alkaline phosphatase predicts mortality among maintenance hemodialysis patients. J Am Soc Nephrol 2008;19:2193-203.
27. Shi YL, Wang LW, Huang J, Gou BD, Zhang TL, Wang K. Lanthanum suppresses osteoblastic differentiation via pertussis toxin-sensitive G protein signalling in rat vascular smooth muscle cells. J Cell Biochem 2009;108:1184-91.
28. Hu J, Jia Y, Liu XT, Li RC, Wang K. Effects of lanthanum on alkaline phosphatase. Beijing Da Xue Xue Bao 2003;35:176-9.
29. Navaneethan SD, Palmer SC, Craig JC, Elder GL, Strippoli GFM. Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials. Am J Kidney Dis 2009;54:619-37.